The University of Arizona

Holiday Party 2011 Announcement

 

Medical Education Journal Club

ARIZONA RESPIRATORY CENTER’S

OLD FASHIONED HOLIDAY PARTY

TUESDAY, December 20, 2011
11:30 A.M. to 5:00 P.M.
Arizona Respiratory Center Hallway
AHSC Building 201 – 2nd Floor

Please join your co-workers at the Arizona Respiratory Center
for a nice old fashion holiday party!!

About the Center

Fernando D. Martinez, MDWelcome to the Arizona Respiratory Center, an internationally renowned organization of physicians, scientists, and scholars all seeking to understand and eradicate respiratory diseases.

SAPS

Summary: 

The purpose of the study is to refine our understanding through the use of questionnaires, of the performance characteristics of these assessments in smoking as compared to non-smoking asthmatics.  



Research Specialties: 
Asthma

SIROCCO

Summary: 

A multicenter, randomized, double-blind parallel group, placebo-controlled phase 3 efficacy and study of Benralizumab added to high-dose ICS plus LABA in patients with uncontrolled asthma.


Researchers: 

Research Specialties: 
Asthma

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Summary: 

The study evaluates the efficacy of fluticasone furoate/umeclidinium bromide/vilanterol (FF/UMEC/VI) to reduce the annual rate of moderate and severe exacerbations compared with dual therapy of FF/VI or UMEC/VI in subjects with COPD. Published studies which assessed the use of an 'open' triple therapy (use of Inhaled Corticosteroid [ICS]/ Long-acting Muscarinic Receptor Antagonists [LAMA])/ Long Acting Beta-Agonist [LABA] delivered via multiple inhalers) in moderate-severe COPD patients, reported improvements in lung function, Health Related Quality of Life (HRQoL), hospitalization rates and rescue medication use, compared to dual therapy (ICS/LABA) or LAMA alone. These studies have also shown similar safety profile with dual or monotherapy doses for periods of up to one year. Given the clinical experience with FF, UMEC and VI, and that the associated risks with these compounds are anticipated from their known pharmacology, the potential benefit of a new therapy option in patients with moderate to severe COPD supports the further development of the closed triple combination (delivered via one inhaler). In the current study subjects meeting all inclusion/exclusion criteria will complete 2-week run-in period; 52 week treatment period and a 1-week safety follow-up period. Eligible subjects will be randomized to one of the following double-blind treatment groups FF/UMEC/VI 100 micrograms (mcg)/62.5 mcg/25 mcg once daily (QD), FF/VI 100 mcg/25 mcg QD, or UMEC/VI 62.5 mcg/25 mcg QD

Sponsor: 
GlaxoSmithKline


Research Specialties: 
Pulmonary

Steroids in Eosinophil Negative Asthma (SIENA)

Summary: 

This study looks at two different inhalers, one inhaled steroid and one long-acting bronchodilator, to find out if people should take an asthma controller medication based on the type of inflammatory cells present in their airways.  


Researchers: 

Research Specialties: 
Asthma

STICS

Summary: 

The purpose of the study is to find the best yellow-zone action plan strategy for children with asthma.


Researchers: 

Research Specialties: 
Asthma

ALfA

Summary: 

The purpose of this study is to find out if alendronate affects the loss of bronchoprotection in patients with asthma who are taking beta-2-agonists.


Researchers: 

Research Specialties: 
Asthma

Pages

Subscribe to Arizona Respiratory Center RSS

Fatal error: Class 'FeedsHTTPCache' not found in /home/arcadmin/public_html/sites/all/modules/feeds/feeds.module on line 82